GPP
Great Point Partners Portfolio holdings
AUM
$154M
This Quarter Return
-12.43%
1 Year Return
-2.36%
3 Year Return
+169.3%
5 Year Return
+292.82%
10 Year Return
+3,519.88%
AUM
$184M
AUM Growth
+$184M
(-13%)
Cap. Flow
+$14.6M
Cap. Flow
% of AUM
7.92%
Top 10 Holdings %
Top 10 Hldgs %
55.21%
Holding
36
New
9
Increased
6
Reduced
8
Closed
4
Top Buys
| 1 |
Akebia Therapeutics
AKBA
|
$9.55M |
| 2 |
Ascendis Pharma
ASND
|
$7.79M |
| 3 |
Amylyx Pharmaceuticals
AMLX
|
$6.41M |
| 4 |
Immunovant
IMVT
|
$6.41M |
| 5 |
Legend Biotech
LEGN
|
$4.69M |
Top Sells
| 1 |
KalVista Pharmaceuticals
KALV
|
$8.92M |
| 2 |
Ionis Pharmaceuticals
IONS
|
$7.69M |
| 3 |
Jasper Therapeutics
JSPR
|
$6.89M |
| 4 |
ORKA
Oruka Therapeutics, Inc. Common Stock
ORKA
|
$4.44M |
| 5 |
Dynavax Technologies
DVAX
|
$3.43M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Cytokinetics
CYTK
$4.23B
| $14.9M | 7.88% | 370,000 +10,000 | +3% | +$402K |
|
|
2
KalVista Pharmaceuticals
KALV
$678M
| $11.7M | 6.2% | 1,014,367 -772,636 | -43% | -$8.92M |
|
3
Evolus
EOLS
$494M
| $11.4M | 6.02% | 944,743 +49,219 | +5% | +$592K |
|
|
ABVX
4
Abivax
ABVX
$6.12B
| $10.2M | 5.42% | 1,638,111 -10,412 | -0.6% | -$65.1K |
|
5
Viridian Therapeutics
VRDN
$1.5B
| $10.1M | 5.36% | 750,000 | – | – |
|
6
Merus
MRUS
$4.98B
| $9.98M | 5.29% | 237,156 +79,064 | +50% | +$3.33M |
|
|
7
Akebia Therapeutics
AKBA
$833M
| $9.55M | 5.06% | +4,973,840 | New | +$9.55M |
|
8
Xenon Pharmaceuticals
XENE
$2.98B
| $8.23M | 4.36% | 245,272 | – | – |
|
|
9
Ascendis Pharma
ASND
$11.8B
| $7.79M | 4.13% | +50,000 | New | +$7.79M |
|
|
10
Dynavax Technologies
DVAX
$1.19B
| $7.73M | 4.09% | 595,879 -264,121 | -31% | -$3.43M |
|
|
11
Ionis Pharmaceuticals
IONS
$6.79B
| $7.54M | 4% | 250,000 -255,007 | -50% | -$7.69M |
|
|
12
Amylyx Pharmaceuticals
AMLX
$836M
| $6.41M | 3.4% | +1,811,996 | New | +$6.41M |
|
|
13
Immunovant
IMVT
$2.56B
| $6.41M | 3.39% | +375,000 | New | +$6.41M |
|
14
Unicycive Therapeutics
UNCY
$74M
| $6.31M | 3.34% | 10,980,000 | – | – |
|
15
Neurogene
NGNE
$264M
| $5.51M | 2.92% | 470,964 +28,203 | +6% | +$330K |
|
16
Dianthus Therapeutics
DNTH
$759M
| $4.99M | 2.64% | 275,000 | – | – |
|
|
17
Legend Biotech
LEGN
$6.41B
| $4.69M | 2.48% | +138,240 | New | +$4.69M |
|
18
Vaxcyte
PCVX
$4B
| $4.36M | 2.31% | +115,517 | New | +$4.36M |
|
|
AUTL
19
Autolus Therapeutics
AUTL
$399M
| $4.23M | 2.24% | 2,728,910 -280,482 | -9% | -$435K |
|
|
BBOT
20
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$708M
| $4.22M | 2.24% | 373,833 -126,167 | -25% | -$1.43M |
|
21
Zura Bio
ZURA
$133M
| $4.09M | 2.17% | 3,170,194 | – | – |
|
22
Beam Therapeutics
BEAM
$1.66B
| $3.43M | 1.82% | +175,562 | New | +$3.43M |
|
23
Arcellx
ACLX
$3.85B
| $2.95M | 1.56% | +45,000 | New | +$2.95M |
|
|
MREO
24
Mereo BioPharma
MREO
$272M
| $2.87M | 1.52% | 1,275,000 +125,000 | +11% | +$281K |
|
25
Context Therapeutics
CNTX
$75.4M
| $2.87M | 1.52% | 4,683,711 | – | – |
|